Ypsomed and CamDiab to Launch iOS Version of mylife Loop Automated Insulin Delivery System
核心洞察
Ypsomed (搜索) and CamDiab (搜索) are launching an iOS version of the mylife CamAPS FX (搜索) app, enabling people with type 1 diabetes (搜索) to manage their automated insulin delivery system directly from iPhones.
The rollout will begin in Sweden on March 24, 2025, initially compatible with Abbott's FreeStyle Libre 3 (搜索) and FreeStyle Libre 3 Plus (搜索) sensors, with Dexcom G6 (搜索) integration to follow.
mylife Loop (搜索) is the only algorithm in Europe and New Zealand approved for pregnant women with type 1 diabetes (搜索), and will expand across Europe, Australia, and Canada throughout 2025.
The diabetes technology landscape is set to expand as Ypsomed (搜索), in collaboration with CamDiab (搜索), announces the upcoming launch of an iOS version for the mylife CamAPS FX (搜索) app, a critical component of their automated insulin delivery (AID) system known as mylife Loop (搜索).
The new iOS compatibility will allow people with type 1 diabetes (搜索) to manage their insulin delivery system directly from their iPhones, offering greater convenience and discretion in diabetes management. The rollout is scheduled to begin on March 24, 2025, in Sweden before expanding to additional markets.
"The introduction of the iOS version of the mylife Loop (搜索) solution is an important step towards the wider availability of AID solutions for the treatment management of type 1 diabetes (搜索)," said Sébastien Delarive, Chief Business Officer Diabetes Care at Ypsomed (搜索).
Professor Roman Hovorka, Director of CamDiab (搜索) Ltd, emphasized the significance of this development: "The expansion of the mylife CamAPS FX (搜索) app to iOS represents a major milestone in making automated insulin delivery more accessible to people with type 1 diabetes (搜索). Our goal is to provide a seamless, user-friendly experience that empowers individuals to better manage their condition with greater flexibility and convenience."
Phased Implementation Strategy
The initial pilot phase in Sweden will feature compatibility with Abbott's FreeStyle Libre 3 (搜索) and FreeStyle Libre 3 Plus (搜索) continuous glucose monitoring (CGM) sensors. Integration with the Dexcom G6 (搜索) sensor will follow in subsequent updates.
After completing the Swedish pilot, Ypsomed (搜索) and CamDiab (搜索) plan to continue the rollout across Europe, followed by Australia and Canada throughout 2025. This phased approach allows the companies to monitor performance and user experience before wider distribution.
Advanced Algorithm Technology
The mylife Loop (搜索) system utilizes an adaptive algorithm that runs on the user's personal smartphone. The system is approved for people with type 1 diabetes (搜索) from one year of age, with specific sensor compatibility requirements. Notably, it stands as the only algorithm in Europe and New Zealand that is also indicated for use by pregnant women with type 1 diabetes.
The complete mylife Loop (搜索) system combines the mylife CamAPS FX (搜索) algorithm with the mylife YpsoPump (搜索) insulin pump and compatible CGM sensors from either Abbott (FreeStyle Libre 3 (搜索) or FreeStyle Libre 3 Plus (搜索)) or Dexcom (搜索) (G6).
Market Availability
Currently, mylife Loop (搜索) is marketed across most European countries, Canada, Australia, and New Zealand. The iOS expansion represents a significant step in increasing accessibility to automated insulin delivery technology.
Ypsomed (搜索) has established itself as a leading developer and manufacturer of injection and infusion systems for self-medication and diabetes care. The company markets its products under the umbrella brand mylife Diabetescare directly to patients, pharmacies, and hospitals, while also operating in business-to-business channels with pharmaceutical companies under Ypsomed Delivery Systems.
CamDiab (搜索) Ltd specializes in digital health and personalized medicine, focusing on the development and commercialization of its interoperable CamAPS FX closed-loop app. The company's technology employs an adaptive, self-learning control algorithm that works with compatible CGM devices and insulin pumps to autonomously calculate and direct insulin delivery for optimal glycemic control.
The expansion to iOS marks an important advancement in making AID technology more accessible to the diverse population of people living with type 1 diabetes (搜索), potentially improving quality of life and diabetes management outcomes for users worldwide.